• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

    9/22/25 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email

    PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer.

    Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world's largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providing patients with neurosurgical care.

    "Dr. Turner's extensive medical and clinical experience and expertise will be significant assets to Integra as we strengthen our focus on building robust clinical evidence," said Mojdeh Poul, president and chief executive officer, Integra LifeSciences. "His proven leadership and passion for advancing safety and quality will help us continue to deliver innovative solutions and transform patient care for the millions around the world."

    Prior to joining Integra, Dr. Turner held various leadership roles at Siemens Healthineers, including his most recent position as the chief medical officer for Siemens Endovascular Robotics. Prior to this, he was a medical director for Cerenovus, a Johnson & Johnson MedTech company. Additionally, Dr. Turner served as the program director of the neurosurgery residency program and was the chief of neuroscience (neurological surgery, neurology, and ENT) at the Medical University of South Carolina.

    "I am excited to be joining Integra, an organization deeply committed to providing best-in-class, evidence-based products that help restore patient lives," said Dr. Raymond Turner. "I look forward to working closely with both the Integra team and our healthcare partners to improve patient outcomes and uphold the highest standards of care."

    Dr. Turner served as a practicing surgeon at PRISMA Health and most recently, at Intermountain Health in Billings, Montana. He currently serves as an examiner for the American Board of Neurological Surgery.

    Dr. Turner completed his undergraduate degree in biology at Sacred Heart University in Connecticut. He obtained his medical degree at Karol Marcinkowski University of Medical Sciences in Poznan, Poland. Dr. Turner completed his residency in neurological surgery and his fellowship in endovascular neurosurgery at the Cleveland Clinic. He has authored more than 150 peer-reviewed publications and has been involved in more than 70 pre-clinical and clinical research studies.

    About Integra LifeSciences

    At Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com.

    Investor Relations:

    Chris Ward

    (609) 772-7736

    [email protected]

    Media:

    Laurene Isip

    (609) 208-8121

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1bd1b51-a9bb-4545-b463-a79108abf93f



    Primary Logo

    Get the next $IART alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IART

    DatePrice TargetRatingAnalyst
    3/31/2025Hold → Buy
    Argus
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    10/7/2024Sell → Neutral
    BTIG Research
    7/30/2024$22.00Neutral → Sell
    BTIG Research
    7/30/2024$30.00 → $23.00Neutral → Sell
    Citigroup
    5/7/2024Outperform → Perform
    Oppenheimer
    5/7/2024$45.00 → $25.00Overweight → Equal Weight
    Wells Fargo
    4/3/2024$38.00Sell → Neutral
    Citigroup
    More analyst ratings

    $IART
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CHRO Veillon-Berteloot Chantal covered exercise/tax liability with 3,551 shares, decreasing direct ownership by 11% to 27,647 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    9/2/25 4:33:40 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Director Essig Stuart disposed of $2,724,000 worth of shares (200,000 units at $13.62) and acquired $2,724,000 worth of shares (200,000 units at $13.62), decreasing direct ownership by 15% to 1,152,236 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    8/18/25 4:43:39 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    EVP & Chief Financial Officer Knight Lea Daniels covered exercise/tax liability with 2,561 shares, decreasing direct ownership by 4% to 58,578 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    7/7/25 5:06:50 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

    PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world's largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providi

    9/22/25 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences

    PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at two upcoming investor healthcare conferences: Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ETMorgan Stanley Healthcare Conference on September 10, 2025, at 8:30 a.m. ET A live webcast of the presentations will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring pati

    8/29/25 4:30:00 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $IART
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/24/24 4:08:19 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/22/24 4:09:18 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integra upgraded by Argus

    Argus upgraded Integra from Hold to Buy

    3/31/25 8:28:08 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Morgan Stanley initiated coverage on Integra with a new price target

    Morgan Stanley initiated coverage of Integra with a rating of Underweight and set a new price target of $20.00 from $25.00 previously

    12/2/24 8:17:21 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra upgraded by BTIG Research

    BTIG Research upgraded Integra from Sell to Neutral

    10/7/24 7:56:40 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Leadership Updates

    Live Leadership Updates

    View All

    Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer

    PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer. Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world's largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providi

    9/22/25 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    $IART
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

    SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 5:20:30 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 12:54:20 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    8/12/24 10:06:35 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Integra LifeSciences Holdings Corporation

    SCHEDULE 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    8/5/25 11:50:40 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Integra LifeSciences Holdings Corporation

    S-8 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    7/31/25 4:51:57 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation

    10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    7/31/25 4:02:56 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    Financials

    Live finance-specific insights

    View All

    Integra LifeSciences Reports Second Quarter 2025 Financial Results

    PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $(6.31), compared to $(0.16) in the prior year primarily reflecting a goodwill impairment charge of $511 million, recorded during t

    7/31/25 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

    PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

    7/14/25 4:35:00 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Reports First Quarter 2025 Financial Results

    PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

    5/5/25 6:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care